FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. PMID 37409323 · EClinicalMedicine · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. PMID 37402581 · J Immunother Cancer · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Endobronchial indocyanine green instillation to identify the intersegmental plane for successful segmentectomy. PMID 37342249 · Respirol Case Rep · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Nomograms for postsurgical extrahepatic recurrence prediction of hepatocellular carcinoma based on presurgical circulating tumor cell status and clinicopathological factors. PMID 37337754 · Cancer Med · 2023-Jul The study is an oncology randomized trial with time-to-event outcomes, but it lacks a drug intervention (assesses a predictive nomogram, not a drug therapy) and does not report Phase III/IIIb or Phase II/III trial results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of a lymphedema prevention program based on the theory of knowledge-attitude-practice on postoperative breast cancer patients: A randomized clinical trial. PMID 37329176 · Cancer Med · 2023-Jul The study is an oncology RCT in humans with an original primary result. However, it is not eligible because: 1) No time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR) is reported; the primary outcomes are lymphedema incidence (proportion), handgrip strength, arm function, and quality of life. 2) The phase of the trial is not specified (no Phase III/IIIb or Phase II/III designation). 3) While the intervention involved a lymphedema prevention program (with chemotherapy as context), the drug intervention (a specific investigational drug) is not established as the primary variable of interest; the study evaluates a nursing/supportive care program. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. PMID 37306107 · Cancer Med · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Dynamic Prediction of Survival for Sinonasal Extranodal Natural Killer/T-cell Lymphoma. PMID 37294046 · Laryngoscope · 2023-Jul The record is an oncology, human, retrospective study that uses randomized cohorts to develop a prognostic nomogram for survival prediction in SN-ENKTL. It is not a report of a Phase III/IIIb or Phase II/III randomized clinical trial with a drug-containing intervention; it lacks evidence of a trial phase and a drug intervention, and it is not a formal trial result report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized trial of exercise on cancer-related blood biomarkers and survival in women with ovarian cancer. PMID 37269192 · Cancer Med · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Genetic and lifestyle factors for breast cancer risk assessment in Southeast China. PMID 37264741 · Cancer Med · 2023-Jul The record is a case-control study examining genetic and lifestyle risk factors for breast cancer, not a randomized clinical trial. It lacks a drug intervention, a time-to-event efficacy endpoint, and the required trial phase. The publication type 'Randomized Controlled Trial' appears to be an error in metadata, as the study methods clearly describe a case-control design. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial. PMID 37245441 · Eur J Cancer · 2023-Jul Cannot establish eligibility because the original trial's phase (Phase III/IIIb or Phase II/III) is not explicitly confirmed in the provided metadata, and this report is a secondary diagnostic comparison analysis, not the primary trial result report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study. PMID 37236033 · Gynecol Oncol · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study. PMID 37229879 · Gynecol Oncol · 2023-Jul The record describes a secondary analysis of a phase III randomized trial in oncology with a drug intervention, but it focuses on safety/toxicity and dosing methodology, not a primary or key secondary time-to-event efficacy endpoint. Therefore, it does not meet the eligibility criteria for KM digitization. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321. PMID 37226421 · Cancer Med · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer. PMID 37226020 · Breast Cancer Res Treat · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours. PMID 37196483 · Eur J Cancer · 2023-Jul This is a pooled analysis of five clinical trials (phase 2 and phase 3) focusing on sex differences in toxicity, not a primary efficacy analysis. It does not report time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR data, and is not an original result report of a single randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A novel prognostic nomogram for adult acute lymphoblastic leukemia: a comprehensive analysis of 321 patients. PMID 37173535 · Ann Hematol · 2023-Jul This is a retrospective prognostic nomogram analysis of acute lymphoblastic leukemia (ALL) patients, a human malignancy. The study includes time-to-event endpoints (OS, PFS) and is described as an original analysis. The 'Randomized Controlled Trial' publication type refers to the random split of data for model training/validation (2:1 ratio), not a randomized drug intervention trial. There is no drug-containing intervention; the analysis compares outcomes with vs. without stem cell transplantation (SCT), which is a procedure, not a drug. The trial phase (Phase III/IIIb or II/III) is not specified in the metadata or abstract. Therefore, it fails the required drug intervention criterion and the phase criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patients. PMID 37169301 · Radiother Oncol · 2023-Jul The record is a randomized trial with drug intervention and includes time-to-event analyses, but the required phase (III/IIIb or II/III) is not explicitly established in the provided metadata or abstract. Additionally, the primary endpoint is safety/toxicity, and while efficacy endpoints are reported, they are secondary with non-significant results, making it unclear if they are the 'primary/key secondary' endpoint for this adjudication. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer. PMID 37167896 · Gynecol Oncol · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours. PMID 37164774 · Eur J Cancer · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours. PMID 37163806 · Eur J Cancer · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32). PMID 37157006 · Breast Cancer Res Treat · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Paternal Combined Botanicals Contribute to the Prevention of Estrogen Receptor-Negative Mammary Cancer in Transgenic Mice. PMID 37146973 · J Nutr · 2023-Jul The study is an original, randomized, oncology-related report, but it is excluded because it is a preclinical animal study (transgenic mice), uses dietary interventions (broccoli sprouts, green tea polyphenols) rather than a drug intervention, and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, TTP, Kaplan-Meier curve, or HR) as required. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Chemoradiotherapy versus triplet chemotherapy as initial therapy for T4b esophageal cancer: survival results from a multicenter randomized Phase 2 trial. PMID 37142731 · Br J Cancer · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF. PMID 37140510 · JACC Heart Fail · 2023-Jul Study is about heart failure with preserved ejection fraction (HFpEF), not oncology. Therefore, it does not meet the primary oncology criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis. PMID 37139963 · Immunotherapy · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study. PMID 37105304 · Radiother Oncol · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib. PMID 37105265 · Ann Oncol · 2023-Jul This is a secondary analysis of a Phase III randomized trial focusing on ctDNA biomarkers and mutational landscape, not the primary efficacy report. While the trial is Phase III, randomized, and includes time-to-event data, this specific report is a biomarker/secondary analysis of the primary trial, not the original formal result. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [TTF-1-negative lung adenocarcinoma: special features of systemic treatment]. PMID 37094793 · Pneumologie · 2023-Jul The abstract describes a randomized trial in oncology with human subjects and a drug intervention, but it is a report of an ongoing study (protocol) without presenting formal efficacy results. There is no signal of a primary or key secondary time-to-event endpoint with results, which is mandatory for inclusion in this cohort. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Prognostic factors and a dynamic model on cancer-specific survival for T1a N0 M0 glottic cancer: A population-based analysis and clinical validation. PMID 37060197 · Clin Otolaryngol · 2023-Jul The study is an observational, population-based prognostic model development and validation, not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention. The 'Randomized Controlled Trial' label is a misnomer for the data splitting, not a true interventional trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Constructing Relative Effect Priors for Research Prioritization and Trial Design: A Meta-epidemiological Analysis. PMID 37057388 · Med Decis Making · 2023-Jul The article is a methodological study presenting Bayesian hierarchical models for constructing prior distributions, using a collection of previous RCTs as input. It is not an original report of a single randomized trial with drug intervention and time-to-event efficacy results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Post-mastectomy radiation therapy in HER-2 positive breast cancer after primary systemic therapy: Pooled analysis of TRYPHAENA and NeoSphere trials. PMID 37030399 · Radiother Oncol · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of Modified Thoracic Breast Approach Lumpectomy on Prognosis of Recurrence in Radical Thyroid Carcinoma Patients. PMID 37023317 · Altern Ther Health Med · 2023-Jul The record describes a randomized trial in thyroid cancer comparing two surgical techniques (endoscopic vs. open thyroidectomy). While it is an oncology RCT with human subjects and original results, it fails several key eligibility criteria: 1) No explicit phase 3 or definitive trial designation; 2) The intervention is purely surgical (no drug-containing arm); 3) The primary endpoints are safety, operative parameters, and short-term biochemical outcomes, with recurrence reported as a binary rate at 1 year, not as a time-to-event analysis with Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the cohort's requirements. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial. PMID 37004887 · Gastroenterology · 2023-Jul The record describes a randomized trial in pediatric Crohn's disease, not a human malignant neoplasm. It is therefore excluded based on the non-oncology criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Optimal treatment strategy and prognostic analysis for hypopharyngeal squamous-cell carcinoma patients with T3-T4 or node-positive: A population-based study. PMID 36977614 · Eur J Surg Oncol · 2023-Jul This is a population-based prognostic study using retrospective SEER data and a single-center cohort to compare treatment modalities (surgery with adjuvant therapy vs. chemoradiotherapy). It is not a report from a prospective randomized controlled trial. The publication type 'Randomized Controlled Trial' appears to be a database error or misclassification, as the study design described is retrospective and observational, not an interventional Phase II/III randomized trial with a drug-containing arm. The intervention is not a drug; it is a comparison of treatment strategies. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| High resection rates of colorectal liver metastases after standardized follow-up and multimodal management: an outcome study within the COLOFOL trial. PMID 36967324 · HPB (Oxford) · 2023-Jul The record describes a randomized trial in oncology with a time-to-event primary endpoint (OS) and presents original results. However, the intervention is a follow-up strategy (high vs. low frequency), not a drug-containing intervention. This fails the 'drug_intervention' criterion. Additionally, the phase of the trial is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III, leaving that criterion unestablished. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data. PMID 36965105 · Eur J Haematol · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Randomized Phase II Study of Irinotecan Plus Cisplatin with or without Simvastatin in Ever-Smokers with Extended Disease Small Cell Lung Cancer. PMID 36960628 · Cancer Res Treat · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. PMID 36948245 · J Thorac Oncol · 2023-Jul This is a secondary analysis of the ORIENT-11 trial, focusing on biomarker classification to predict treatment efficacy. While the underlying trial is randomized and reports time-to-event efficacy for a drug intervention, this specific report does not present the primary results of the trial itself, and the trial phase is not definitively confirmed as Phase III or II/III in the provided information. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. PMID 36939854 · Cancer Immunol Immunother · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. PMID 36931693 · Ann Rheum Dis · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol. PMID 36871111 · Ther Innov Regul Sci · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). PMID 36797449 · BJU Int · 2023-Jul 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study. PMID 36791768 · Cancer Res Treat · 2023-Jul The record describes a randomized trial with a drug intervention and a time-to-event primary endpoint (PFS) in oncology. However, the phase of the trial is not explicitly stated in the provided metadata (title, abstract, publication types) as Phase III/IIIb or Phase II/III. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit confirmation of the phase from the formal report, eligibility cannot be established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies. PMID 36701846 · Cancer Res Treat · 2023-Jul The study is a randomized Phase 3 oncology trial with a drug intervention and reports original results. However, the primary efficacy endpoint is the mean duration of severe neutropenia (a continuous endpoint), not a time-to-event outcome like OS, PFS, DFS, EFS, RFS, TTP, or an analysis using Kaplan-Meier/HR. Therefore, it does not meet the required criteria for time-to-event efficacy endpoints. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Can white-light endoscopy or narrow-band imaging avoid biopsy of colorectal endoscopic mucosal resection scars? A multicenter randomized single-blind crossover trial. PMID 36690030 · Endoscopy · 2023-Jul The study is an oncology randomized trial, but it does not meet the core eligibility criteria. The intervention is not drug-containing (compares endoscopic imaging modalities), and the primary endpoint is diagnostic accuracy (sensitivity/specificity), not a time-to-event efficacy outcome like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Airflow limitation and mortality during cancer screening in the National Lung Screening Trial: why quantifying airflow limitation matters. PMID 36456179 · Thorax · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score. PMID 36369395 · J Cancer Res Clin Oncol · 2023-Jul The study is a retrospective analysis of a randomized trial, but the phase is not explicitly stated as Phase III, Phase IIIb, or Phase II/III. The deterministic review indicates phase3_evidence_unclear. Without clear evidence of a definitive phase (Phase III/IIIb or Phase II/III), it does not meet the primary eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of standard versus extended lymphadenectomy in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A Chinese multi-center prospective randomized controlled trial. PMID 36198383 · J Adv Res · 2023-Jul The record is a randomized, human, oncology trial with a time-to-event primary endpoint and all patients received chemotherapy. However, it is not eligible because it is not a Phase III or Phase II/III trial (phase is unspecified and cannot be assumed), and the primary comparison is between surgical techniques (lymphadenectomy extents), not a drug-containing intervention versus a control. The drug (chemotherapy) was administered to both arms and is not the variable under investigation. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study. PMID 36075994 · J Cancer Res Clin Oncol · 2023-Jul The study is a randomized, drug-intervention trial with primary time-to-event efficacy endpoints. However, the explicit trial phase (e.g., Phase III) is not stated in the provided metadata or abstract, preventing definitive eligibility confirmation. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and influencing factors of Insect Compound Particle combined with chemotherapy for mismatch repair-related locally advanced stage III CRC who had undergone surgery and achieved R0 resection: a multicenter, double-blind, randomized, placebo-controlled clinical trial protocol. PMID 36819567 · Ann Transl Med · 2023-Jan-31 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |